GlaxoSmithKline's (GSK) $54 Billion Consume Arm Said to Draw Buyout Firms - Bloomberg
- Apple (AAPL) Reports In-Line Q4 EPS, Revs Miss
- Amazon (AMZN) Stock Dumps 3% Following Q3 Miss
- S&P, Nasdaq hit record closing highs on earnings bullishness
- Facebook (FB) to Change Name to 'Meta', Ticker to 'MRVS'
- Ford Motor (F) Stock Rallies After Smashing Estimates and Raising Guidance, Reinstated Dividend, Analysts Bulled-up
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
GlaxoSmithKline's (NYSE: GSK) consumer unit is drawing interest from private equity firms as it prepares to split off the business. Advisers are informally fielding interest in the operations alongside preparations for a listing.
Advent, Blackstone (NYSE: BX), The Carlyle Group (NASDAQ: CG), CVS Capital Partners, KKR & Co. (NYSE: KKR) and Permira are among potential suitors for the business It could also attracted some of the worlds biggest pharma and consumer companies.
The unt could be valued at $54 billion or more.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis's (NVS) Sandoz Said Valued at Over $20 Billion as Standalone Unit - Bloomberg
- American Electric Power (AEP) Sells Kentucky Operations To Algonquin's (AQN) Liberty for $2.846B
- Third Point Has Stake in Royal Dutch Shell (RDS-A), Urges Separation Into Two - DJ
Create E-mail Alert Related CategoriesHot M&A, Mergers and Acquisitions, Private Equity, Rumors, Spinoffs
Related EntitiesThe Carlyle Group, Permira
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!